Segal Trials’ Post

🎊 Treating obsessive-compulsive disorder often necessitates the use of additional medications alongside the primary treatment. Our recent study explores one such medication. For more information, you can check out "The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials" at the link provided: https://lnkd.in/dt6PHZR5

An evaluation comparing TMS and ECT treatments indicated that TMS, specifically targeting the left DLPFC, achieved a higher remission rate with an 82% response rate. In contrast, ECT showed a response rate ranging from 75% to 83%. rTMS is a non-invasive therapy that does not require hospitalization, unlike ECT. It is favored for managing depression symptoms in patients with Major Depressive Disorder (MDD). For further insights into these treatment options, stay informed with Sebers Medical.

Discover the breakthrough findings from controlled clinical trials using TMS for Major Depressive Disorder (MDD). With approximately 1 in 3 patients experiencing complete symptom relief and no side effects associated with antidepressants, TMS offers a promising alternative. Explore the potential of owning your own TMS device at sebersmedical.com

these are major factors

Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #NeuroStarConnects #NeuroStar #NeuroStarSocial

Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan. Visit neurostar.com for full safety and prescribing information. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #NeuroStarProvider #NeuroStarConnects #NeuroStar #NeuroStarSocial

Medication isn’t the only route to relief. If your adolescent is experiencing depression, Nurowav TMS is a safe and effective in-office treatment as an add-on therapy. Using NeuroStar technology, we send magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. In a clinical study of 1,169 adolescent patients: 78% cited improvement in their depression symptoms* 48% showed symptom relief (remission)* Visit nurowavtms.com or call our practice today at 267-354-2894 for more information and to learn more about adding TMS to your loved one’s current treatment plan. *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment. #TMS #NeuroStarProvider #NeuroStar #adolescentdepression

Register for our upcoming webinar, April 9th, 1:00-1:50 pm EDT, where we will explore real-world data collected from some of the most complex CNS patient populations - including those with depression, schizophrenia, Agitation in Alzheimer’s, and others - using the spencer SmartHub™. Join us as we share our direct patient feedback and trends regarding adherence, medication satisfaction, technology use, and more. Don’t miss this opportunity to uncover valuable insights as you plan future clinical trials, RWD studies, or patient support programs in CNS diseases. Register here: https://bit.ly/4cxYyOK #webinar #clinicaltrials #patientinsights #RWD

The clinical outcomes from medication-assisted treatment (MAT) programs for the treatment of opioid use disorder are a testament to the critical importance of continuous enrollment in treatment. New evidence revealed in the 2023 Nationwide Opioid Use Disorder Treatment Outcomes Report overwhelmingly supports MAT for those suffering from opioid use disorder. Download the whitepaper here to learn more about the latest documented MAT outcomes of approximately 39,000 undergoing MAT for opioid use disorder: https://lnkd.in/gkUsXCTA